# NanoString Establishes Netherlands Cancer Institute as a Center of Excellence for Digital Spatial Profiling

June 18, 2018

**First Center of Excellence to Focus on Clinical Research and Biomarker Development**

SEATTLE, June 18, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the Netherlands Cancer Institute will become the first in a series of Centers of Excellence (COE) for NanoString's Digital Spatial Profiling (DSP) platform.

The goal of the COE program is to establish a global network of centers with expertise in distinct research areas to expand the utility of the DSP platform. Centers of Excellence will be the first to have access to DSP and an emerging menu of content. Each COE will establish a consortium of users and conduct technology workshops to increase awareness of DSP and generate impactful data demonstrating the utility of highly multiplexed spatial analysis. The Netherlands Cancer Institute will lead the European Center of Excellence with specific expertise in clinical applications and biomarker development on the DSP platform.

"We are excited to lead the DSP Center of Excellence to develop clinical research applications and identify novel biomarkers on this platform," said Dr. Christian Blank, Group Leader of Immunology at the Netherlands Cancer Institute. "Already DSP has provided us with independent validation of mechanisms of relapse following combination immunotherapy in melanoma, and we believe this partnership will lead to more discoveries in the field of oncology with the potential to impact the way we think of treatment."

"Establishing Centers of Excellence will enhance the awareness and establish the utility of the Digital Spatial Profiling platform for clinical research and biomarker development," said Chad Brown, senior vice president of sales & marketing at NanoString. "We look forward to working with Dr. Blank and the Netherlands Cancer Institute to demonstrate the unique capabilities of our DSP technology in advance of our full commercial launch expected in the first half of 2019."

**About the Netherlands Cancer Institute**

The Netherlands Cancer Institute is at the international forefront of cancer care and research for already more than a century. The unique combination of health care and scientific research within the same institute offers great benefit for cancer patients. Specialized cancer care professionals work together in multidisciplinary teams every day to set up and carry out treatment plans tailored to the needs of individual patients because no two tumors are alike. Cancer patients or people suspected of having cancer can come to our hospital, known as the Antoni van Leeuwenhoek, to make use of this personal approach and the state-of-the-art research and treatment facilities. The research institute employs more than 650 scientists investigating many aspects of cancer development, diagnosis, treatment and epidemiology. Scientists at the Netherlands Cancer Institute have access to state-of-the-art research facilities supporting their basic, translational and clinical research. This scientific research could not be carried out without the institutional support of the Dutch Cancer Society, the Ministry of Health, Welfare and Sport, the many research grants obtained by our researchers from (inter)national funding agencies, and the generous donations made by individuals that support our research program. The Netherlands Cancer Institute is the only OECI designated Comprehensive Cancer Center in the Netherlands. For more information please visit our websites www.nki.nl and www.avl.nl.

**About NanoString Technologies, Inc.**

NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 2,000 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company collaborates with biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.

For more information, please visit www.nanostring.com.



**Contact:**

**Doug Farrell**
Vice President, Investor Relations & Corporate Communications
**dfarrell@nanostring.com**
**Phone: 206-602-1768**

Source: NanoString Technologies, Inc.